NCT02126956View on ClinicalTrials.gov

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Pharmacokinetics

Interventions

DRUG

ACT-128800

ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).

Trial Locations (1)

Unknown

Swiss Pharma Contract, Allschwil